User:Mr. Ibrahem/Vestronidase alfa

Vestronidase alfa, sold under brand name Mepsevii, is a medication used to treat mucopolysaccharidosis type VII (Sly syndrome). It is given by injection into a vein over four hours.

Common side effects include swelling at the site of injection, diarrhea, rash, and anaphylaxis. It is a recombinant form of the human enzyme beta-glucuronidase; and works by replacing this missing enzyme.

Vestronidase alfa was approved in the United States in 2017 and Europe in 2018. In the United States it costs about 2,400 USD for 10 mg as of 2021 or about 624,000 USD a year for someone who weights 25 kg.